Utah Medical Products Inc.

UTMD · Nasdaq · Healthcare · Medical Instruments and Supplies

Next earnings: October 22, 2026

$74.18-0.8%Sep 25 close

1M: +2.4%
6M: +21.6%
1Y: +20.4%
5Y: -14.1%

How it compares with its industry

Three ratings, each a percentile against the 50 companies we cover in Medical Instruments and Supplies. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.

Momentum

70of 100 in its industry

Above most of its industry

12 months to a month ago19.9%

6 months to a month ago5.8%

The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.

Value

69of 100 in its industry

Above most of its industry

Profit for the price4.44%

Cash for the price4.85%

Sales for the price15.29%

Assets for the price50.50%

Operating profit for the whole business9.51%

Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. All five measures available.

Capital allocation

3/5Mixed

1 check not reported

Return on capital7.5%

Shareholder yield5.22%

Share count, 3 years-12.6%

Net debt / EBITDA-5.94x

Insiders, 12 months—

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money invested7.5% on invested capital
Debt against earningsMore cash than debt
Cash returned to shareholders5.2% a year in buybacks and dividends
Share count over three yearsShare count 12.6% lower over three years
Payouts covered by cash flowPays out more than it generates
Open-market insider buyingNo open-market insider dealing on file

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.

How it compares with its industry

Momentum

70of 100 in its industry

Above most of its industry

12 months to a month ago19.9%

6 months to a month ago5.8%

Value

69of 100 in its industry

Above most of its industry

Profit for the price4.44%

Cash for the price4.85%

Sales for the price15.29%

Assets for the price50.50%

Operating profit for the whole business9.51%

Capital allocation

3/5Mixed

1 check not reported

Return on capital7.5%

Shareholder yield5.22%

Share count, 3 years-12.6%

Net debt / EBITDA-5.94x

Insiders, 12 months—

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money invested7.5% on invested capital
Debt against earningsMore cash than debt
Cash returned to shareholders5.2% a year in buybacks and dividends
Share count over three yearsShare count 12.6% lower over three years
Payouts covered by cash flowPays out more than it generates
Open-market insider buyingNo open-market insider dealing on file

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.

How it compares with its industry

How it compares with its industry

Growth & cash — 1 of 5